US draft law would toughen penalties against counterfeiting, especially drugs

27 May 2007

Violations of intellectual property rights not only deprive legitimate businesses of millions of dollars and undercut innovation but often pose serious threat to human safety and health, according to US Attorney General Alberto Gonzales.

In response to this problem, the US Justice Department on May 14 sent to Congress the Intellectual Property Protection Act of 2007. The draft legislation calls for stronger penalties for repeat offenders and would also increase the maximum penalty for counterfeiting offenses if the defendant "knowingly and recklessly causes serious bodily injury or death," said AG Gonzales.

To be considered by Congress, a draft bill sent by the administration must be sponsored by one or more members of Congress. To become a law, identical versions of a bill must be passed by both chambers of Congress and signed by the President.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight